Missions & history
PHAGENIX, is a new specialty pharma
2025
Our mission
INNOVATIVE APPROACH
PHAGENIX relies on an innovative approach based on the use of phages, natural bacteria-killing viruses, with a targeted approach, to fight resistant bacterial infections.
PHAGES PORTFOLIO
PHAGENIX is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, responsible for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.